Citalopram and Pramipexole in depression in Parkinson disease
Phase 2
- Conditions
- Parkinson disease.Parkinson's disease
- Registration Number
- IRCT20191111045407N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Controlled disease with monotheraphy with Levodopa
Exclusion Criteria
Cognitive disorders
Psychotic disorders and suicidal thought or attempt
Use of antipsychotics, anticholinergics, dopamine agonists and other psychological drugs and therapies
Use of metoclopramide, methyldopa, methylphenidate, reserpine, flunarizine, Cinnarizine and amphetamine derivatives within the past 3 months
History of malignant melanoma
History of previous deep brain stimulation surgery
Pregnancy
Lactating
using contraceptive drugs
Off” period for greater than 50% of the day
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Beck depression inventory total score. Timepoint: Assessment of depression score in Beck depression inventory at baseline (before intervention) and 8 weeks after starting pramipexole or citalopram. Method of measurement: Beck depression inventory.
- Secondary Outcome Measures
Name Time Method Quality of life score. Timepoint: Assessment of quality of life score with Parkinson's Disease Questionnaire at baseline (before intervention) and 8 weeks after starting pramipexole or citalopram. Method of measurement: Parkinson's Disease Questionnaire.